

PERFORMANCE IN DELIVERING CLINICAL RESEARCH – Q1 (2018/19)



IRAS No	REC No	Name of Trial	Target Number of Patients Agreed	Target Recruitment	Minimum No	Maximum No	Target Date to recruits patient agreed?	Date Agreed to recruit target number of patients	Total Recruited by agreed date	Total of Study Participants Recruited	Date closed to Recruitment	Reason for Closure
199977	16/SC/0203	Safety and efficacy of BGS649 in male obese patients with HH	Number Agreed	3	3	3	Date Agreed	31/08/2017	3	3	31/08/2017	Recruitment Finished
198595	16/EM/0125	A Prospective Randomized Controlled Multi-Centre Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies	Range Agreed	20	20	40	Date Agreed	31/12/2017	38	38	25/07/2017	Recruitment Finished
199366	16/LO/1386	IDDEA-HF	Number Agreed	4	4	4	Date Agreed	31/07/2017	0	0	26/07/2017	Recruitment Finished
225662	17/YH/0116	SUSTAIN-10	Number Agreed	8	8	8	Date Agreed	14/11/2017	19	19	14/11/2017	Recruitment Finished
192513	15/LO/2047	MEDI2070 in Moderate to Severe Crohn's Disease	Number Agreed	2	2	2	Date Agreed	16/10/2017	0	0	25/08/2017	Recruitment Finished
131006	13/LO/0826	CCRN 2553 (C Diff vaccine)	Number Agreed	25	25	25	Date Agreed	17/11/2017	47	47	17/11/2017	Withdrawn by Sponsor
189127	15/NW/0786	GAST 5090	Number Agreed	3	3	3	Date Agreed	31/05/2017	3	3	31/08/2017	Recruitment Finished
180533	15/WM/0316	GAST 4608 (Inflammatory Bowel Disease)	Number Agreed	10	10	10	Date Agreed	01/12/2017	18	18	31/10/2017	Recruitment Finished
181394	15/NW/0519	GAST 4560	Number Agreed	20	20	20	Date Agreed	10/09/2015	20	20	29/11/2017	Recruitment Finished
211430	16/EM/0376	RENA 5499	Number Agreed	1	1	1	Date Agreed	31/03/2018	7	7	31/03/2018	Recruitment Finished
198058	17/LO/0064	Study of Mirvetuximab Soravtansine vs standard cancer treatments	Number Agreed	2	2	2	Date Agreed	21/06/2018	1	1	26/04/2018	Recruitment finished